


EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	729	(544/330).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/09/20 18:50
L2	3098	((544/323,324,331,332) or (514/275)). CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/09/20 18:50
L3	3447	1 or 2	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/09/20 18:50



chain nodes :

7 8 9 11 13 14 15 16 17 18 19 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
37 38 39 40 41 42 43 44 45 46 58 61

ring nodes :

1 2 3 4 5 6

chain bonds :

1-61 3-7 5-58 6-9 7-8 11-13 11-13 14-15 16-17 18-19 18-21 22-23 23-24 23-25 26-27 27-28
29-30 30-31 30-32 33-34 33-35 36-37 37-38 39-41 39-40 39-42 43-44 44-45 44-46

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

3-7 5-58 7-8 11-13 11-13 14-15 16-17 18-19 18-21 22-23 23-24 23-25 26-27 27-28 29-30 30-31
30-32 33-34 33-35 36-37 37-38 39-41 39-40 39-42 43-44 44-45 44-46

exact bonds :

1-61 6-9

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:O,S

G2:C,SO2,[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9],[*10],[*11]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:Atom 9:CLASS11:Atom 13:CLASS14:CLASS
15:CLASS16:CLASS17:CLASS18:CLASS19:CLASS21:CLASS22:CLASS23:CLASS24:CLASS25:CLASS
26:CLASS27:CLASS28:CLASS29:CLASS30:CLASS31:CLASS32:CLASS33:CLASS34:CLASS35:CLASS
36:CLASS37:CLASS38:CLASS39:CLASS40:CLASS41:CLASS42:CLASS43:CLASS44:CLASS45:CLASS
46:CLASS58:CLASS61:CLASS


Generic attributes :

8:
Saturation : Unsaturated

10/812,293

=>

Uploading C:\Program Files\Stnexp\Queries\10812293.str



chain nodes :
7 8 9 12
ring nodes :
1 2 3 4 5 6
chain bonds :
3-7 7-8
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
3-7 7-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:C,O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:Atom
12:CLASS 13:Atom

Generic attributes :

8:


Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 17:26:51 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 648 TO ITERATE

100.0% PROCESSED 648 ITERATIONS

23 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 11433 TO 14487

PROJECTED ANSWERS: 173 TO 747

L2 23 SEA SSS SAM L1

=> =>

Uploading C:\Program Files\Stnexp\Queries\10812293 (a).str



```

chain nodes :
7  8  9  14  15  16  17  18  19  20  22  23  24  25  26  27  28  29  30  31  32  33
34  35  36  37  38  39  40  41  42  43  44  45  46  47  61
ring nodes :
1  2  3  4  5  6  12
chain bonds :
3-7  7-8  12-14  15-16  17-18  19-20  19-22  23-24  24-25  24-26  27-28  28-29
30-31  31-32  31-33  34-35  34-36  37-38  38-39  40-42  40-41  40-43  44-45  45-46
45-47
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  12-13
exact/norm bonds :
3-7  7-8  12-13  12-14  15-16  17-18  19-20  19-22  23-24  24-25  24-26  27-28
28-29  30-31  31-32  31-33  34-35  34-36  37-38  38-39  40-42  40-41  40-43  44-45
45-46  45-47
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :

```

G1:O,S

G2:[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9],[*10],[*11]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:Atom
 12:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS
 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS
 46:CLASS 47:CLASS 61:CLASS 62:Atom

Generic attributes :

8:

Saturation : Unsaturated

18:

Saturation : Saturated

Number of Carbon Atoms : less than 7

L3 STRUCTURE UPLOADED

=> d' l3

L3 HAS NO ANSWERS

L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l3 sss sam

SEARCH FAILED DUE TO A STRUCTURE QUERY ERROR

The structure query could not be searched. Please review and revise your structure query, especially checking the variable definitions and attachments. In rare instances the failure may be due to a system problem. Please contact your local STN Help Desk if you need assistance.

=>

Uploading C:\Program Files\Stnexp\Queries\10812293 (b).str



chain nodes :

7 8 9 14 15 16 17 18 19 20 22 23 24 25 26 27 28 29 30 31 32 33
34 35 36 37 38 39 40 41 42 43 44 45 46 47 59

ring nodes :

1 2 3 4 5 6 12

chain bonds :

3-7 7-8 12-14 15-16 17-18 19-20 19-22 23-24 24-25 24-26 27-28 28-29
30-31 31-32 31-33 34-35 34-36 37-38 38-39 40-42 40-41 40-43 44-45 45-46
45-47

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 12-13

exact/norm bonds :

3-7 7-8 12-13 12-14 15-16 17-18 19-20 19-22 23-24 24-25 24-26 27-28
28-29 30-31 31-32 31-33 34-35 34-36 37-38 38-39 40-42 40-41 40-43 44-45
45-46 45-47

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:O,S

G2:C,SO2,[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9],[*10],[*11]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:Atom
 12:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS
 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS
 46:CLASS 47:CLASS 59:CLASS 60:Atom

Generic attributes :

8:

Saturation : Unsaturated

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l4 sss sam

SEARCH FAILED DUE TO A STRUCTURE QUERY ERROR

The structure query could not be searched. Please review and revise your structure query, especially checking the variable definitions and attachments. In rare instances the failure may be due to a system problem. Please contact your local STN Help Desk if you need assistance.

=>

Uploading C:\Program Files\Stnexp\Queries\10812293 (d).str



chain nodes :

7 8 9 11 13 14 15 16 17 18 19 21 22 23 24 25 26 27 28 29 30 31
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 58

ring nodes :

1 2 3 4 5 6

chain bonds :

3-7 5-58 7-8 11-13 11-13 14-15 16-17 18-19 18-21 22-23 23-24 23-25
26-27 27-28 29-30 30-31 30-32 33-34 33-35 36-37 37-38 39-41 39-40 39-42
43-44 44-45 44-46

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

3-7 5-58 7-8 11-13 11-13 14-15 16-17 18-19 18-21 22-23 23-24 23-25
26-27 27-28 29-30 30-31 30-32 33-34 33-35 36-37 37-38 39-41 39-40 39-42
43-44 44-45 44-46

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:O,S

G2:C,SO2,[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9],[*10],[*11]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 11:Atom
 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 21:CLASS
 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS
 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS
 46:CLASS 58:CLASS 61:CLASS

Generic attributes :

8:

Saturation : Unsaturated

L5 STRUCTURE UPLOADED

=> d l5

L5 HAS NO ANSWERS

L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l5 sss sam

SAMPLE SEARCH INITIATED 17:42:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 398 TO ITERATE

100.0% PROCESSED 398 ITERATIONS

15 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 6764 TO 9156

PROJECTED ANSWERS: 68 TO 532

L6 15 SEA SSS SAM L5

=> =>

Uploading C:\Program Files\Stnexp\Queries\10812293 (e).str



```

chain nodes :
7  8  9  11  13  14  15  16  17  18  19  21  22  23  24  25  26  27  28  29  30  31
32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  58  61
ring nodes :
1  2  3  4  5  6
chain bonds :
1-61  3-7  5-58  6-9  7-8  11-13  11-13  14-15  16-17  18-19  18-21  22-23  23-24
23-25  26-27  27-28  29-30  30-31  30-32  33-34  33-35  36-37  37-38  39-41  39-40
39-42  43-44  44-45  44-46
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
3-7  5-58  7-8  11-13  11-13  14-15  16-17  18-19  18-21  22-23  23-24  23-25
26-27  27-28  29-30  30-31  30-32  33-34  33-35  36-37  37-38  39-41  39-40  39-42
43-44  44-45  44-46
exact bonds :
1-61  6-9
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :

```

G1:O,S

G2:C,SO2,[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9],[*10],[*11]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 11:Atom
 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 21:CLASS
 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS
 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS
 46:CLASS 58:CLASS 61:CLASS

Generic attributes :

8:

Saturation : Unsaturated

L7 STRUCTURE UPLOADED

=> d 17

L7 HAS NO ANSWERS

L7 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 17 sss sam

SAMPLE SEARCH INITIATED 17:45:31 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 126 TO ITERATE

100.0% PROCESSED 126 ITERATIONS

13 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1847 TO 3193

PROJECTED ANSWERS: 44 TO 476

L8 13 SEA SSS SAM L7

=> => s 17 sss ful

FULL SEARCH INITIATED 17:46:39 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2844 TO ITERATE

100.0% PROCESSED 2844 ITERATIONS

274 ANSWERS

SEARCH TIME: 00.00.01

L9 274 SEA SSS FUL L7

=> => s 19

L10 10 L9

=> d 110 1-10 bib,ab,hitstr

L10 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:550943 CAPLUS
 DN 141:106492
 TI Preparation of pyrimidine derivatives for the treatment of abnormal cell growth in cancer
 IN Kath, John Charles; Luzzio, Michael Joseph
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056786	A2	20040708	WO 2003-IB6055	20031217
	WO 2004056786	A3	20041021		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004220177	A1	20041104	US 2003-734039	20031211
	CA 2510848	AA	20040708	CA 2003-2510848	20031217
	AU 2003288603	A1	20040714	AU 2003-288603	20031217
	EP 1578732	A2	20050928	EP 2003-780443	20031217
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003017435	A	20051116	BR 2003-17435	20031217
	JP 2006515298	T2	20060525	JP 2004-561885	20031217
	NL 1025071	A1	20040622	NL 2003-1025071	20031218
	NL 1025071	C2	20041230		
PRAI	US 2002-435670P	P	20021220		
	WO 2003-IB6055	W	20031217		

OS MARPAT 141:106492

AB The title compds. [I; wherein R1 = Q1; wherein D = independently (un)substituted CH or N, with the proviso that R1 is linked to NH group through a ring carbon atom; wherein E, G = N, C; X, W, Q = N, O, S, SO2, CO, NR3, CR2, CR2R3; Y and Z are independently present or absent, if present, Y, Z = N, O, S, SO2, CO, NR3, CR2 and CR2R3; wherein A is present or absent, if present, A = O, S, NH; B is present or absent, if present, B = CO, SO2, or NR6, with the proviso that when A is O or S and B is absent; n = an integer from 1-3; R2 = H, C1-6 alkyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, O-C1-6 alkyl, O-C3-7 cycloalkyl, O-C4-7 heterocycloalkyl, NH2, NHR6, NR6R7, SR6, SOR6, SO2R6, CO2R6, CONH2, CONHR6, CONR6R7, SO2NH2, SO2NHR6, SO2NR6R7, NHCOR6, NR6CONR6, NHCONHR, NR6CONHR, NHCONR6R7, NR6CONR6R7, NHSO2R6, NR6SO2R6, etc.; R3 = H, C1-6 alkyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, CO2R6, CONH2, CONHR5, CONR6R7 or CR2R3 taken together can form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring; R4 = H, C1-6 alkyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, etc.; R5 = H, Br, Cl, cyano, CF3, CH2F, CHF2, SO2Me, CONH2, cyclopropyl, cyclobutyl, Ph, CONHR6, CONR6R7, CO2R6, etc.; R6, R7 = group listed in R3] or pharmaceutically acceptable salts, prodrugs and solvates thereof are

prepared These compds. are selective inhibitors of non-receptor FAK protein tyrosine kinase (no data). The invention also relates to methods of treating abnormal cell growth, in particular cancer, in mammals by administering the compds. I and to pharmaceutical compns. containing the compds. I for treating such disorders. The said cancer is selected from lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, col on cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers. Thus, N-(5-Bromo-2-chloropyrimidin-4-yl)-N-(p-tolyl)amine was aminatred with 4-(5-Amino-1H-indol-3-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-Bu ester in the presence of triethylamine in dioxane at 100° for 16 h to give 4-[5-[5-Bromo-4-(p-tolylamino)pyrimidin-2-ylamino]-1H-indol-3-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-Bu ester which was treated with HCl in a mixture of MeOH and dioxane at room temperature for 6 h to give 5-Bromo-N2-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N4-(p-tolyl)pyrimidine-2,4-diamine hydrochloride.


IT 719315-11-4P, 2-[(2-Oxo-2,3-dihydro-1H-indol-5-yl)amino]-4-[[pyridin-2-yl)methyl]amino]pyrimidine-5-carbonitrile
 719315-16-9P, 2-[(2-Oxo-2,3-dihydro-1H-indol-5-yl)amino]-4-(2-trifluoromethylbenzylamino)pyrimidine-5-carbonitrile 719315-23-8P
 , 2-[(2-Oxo-2,3-dihydro-1H-indol-6-yl)amino]-4-[[pyridin-2-yl)methyl]amino]pyrimidine-5-carbonitrile

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as selective inhibitors of non-receptor tyrosine kinase for treatment of abnormal cell growth, in particular cancers)


RN 719315-11-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-4-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 719315-16-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-4-[[[2-(trifluoromethyl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 719315-23-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-2-oxo-1H-indol-6-yl)amino]-4-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:467870 CAPLUS

DN 141:38625

TI Preparation of Chk-, pdk- and akt-inhibitory pyrimidines

IN Bryant, Judi; Kochanny, Monica; Yuan, Shendong; Khim, Seock-Kuy; Buckman, Brad; Arnaiz, Damian; Boemer, Ulf; Briem, Hans; Esperling, Peter; Huwe, Christoph; Kuhnke, Joachim; Schaefer, Martina; Wortmann, Lars; Kosemund, Dirk; Eckle, Emil; Feldman, Richard; Phillips, Gary

PA Schering Aktiengesellschaft, Germany

SO PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004048343	A1	20040610	WO 2003-EP13443	20031128
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2502970	AA	20040610	CA 2003-2502970	20031128
	AU 2003288198	A1	20040618	AU 2003-288198	20031128
	US 2004186118	A1	20040923	US 2003-722591	20031128
	EP 1565446	A1	20050824	EP 2003-780086	20031128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016680	A	20051018	BR 2003-16680	20031128
	CN 1717396	A	20060104	CN 2003-80104544	20031128
	JP 2006508997	T2	20060316	JP 2004-554522	20031128
	NO 2005003144	A	20050627	NO 2005-3144	20050627
PRAI	EP 2002-26607	A	20021128		
	WO 2003-EP13443	W	20031128		

OS MARPAT 141:38625

AB The title compds. [I; A, B = CN, halo, H, OH, etc.; X = O, (un)substituted NH; R1 = H, halo, CH2OH, alkyl, etc.; R2 = H, (un)substituted NHCO-aryl or alkyl] which are inhibitors of kinases useful as medications for treating various diseases, were prepared E.g., a multi-step synthesis of 5-bromo-4-[2-(1H-imidazol-4-yl)ethylamino]-2-(4-pyrrolidin-1-ylmethylphenylamino)pyrimidine, starting from 5-bromouracil, was given. Biol. data for inhibition of Akt-2, Chk-1, and VEGFR-II (KDR) were given. The pharmaceutical composition comprising the compds. I is claimed.


IT 702675-64-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Chk-, pdk- and akt-inhibitory pyrimidines)

RN 702675-64-7 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[3-[[5-cyano-4-[[3-[(2-thienylcarbonyl)amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:236703 CAPLUS
 DN 140:423636
 TI Solid-Phase Synthesis of 2,4-Diaminopyrimidines via Lewis Acid-Mediated
 Aromatic Nucleophilic Substitution
 AU Arvanitis, Elena A.; Chadha, Naresh; Pottorf, Richard S.; Player, Mark R.
 CS 3-Dimensional Pharmaceuticals Inc., Cranbury, NJ, 08512, USA
 SO Journal of Combinatorial Chemistry (2004), 6(3), 414-419
 CODEN: JCCHFF; ISSN: 1520-4766
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 140:423636
 AB Primary amines were immobilized on (4-formyl-3,5-
 dimethoxyphenoxy)methylpolystyrene resin via reductive amination.
 Attachment of two different 4-chloro-2-methylthiopyrimidines, followed by
 sulfide oxidation, led to the sulfone intermediates. Aromatic nucleophilic
 substitution with various anilines or heteroarom. amines in the presence
 of trimethylaluminum afforded the desired 2,4-diaminopyrimidines after
 acidic cleavage from the resin. The synthetic methodol. described herein
 was validated with the synthesis of a small 162-member library.

IT 691404-25-8P 691404-28-1P 691404-31-6P
 691404-34-9P 691404-36-1P 691404-39-4P
 691404-42-9P 691404-45-2P 691404-48-5P
 691404-51-0P 691404-54-3P 691404-57-6P
 691404-59-8P 691404-62-3P 691404-65-6P
 691404-68-9P 691404-71-4P 691404-74-7P
 691404-77-0P 691404-80-5P 691404-83-8P
 691404-85-0P 691404-87-2P 691404-89-4P
 691404-91-8P 691404-93-0P 691404-96-3P
 691404-99-6P 691405-02-4P 691405-04-6P
 691405-06-8P 691405-08-0P 691405-10-4P
 691405-12-6P 691405-14-8P 691405-16-0P
 691405-18-2P 691405-20-6P 691405-22-8P
 691405-24-0P 691405-26-2P 691405-28-4P
 691405-30-8P 691405-32-0P 691405-34-2P
 691405-37-5P 691405-39-7P 691405-41-1P
 691405-43-3P 691405-45-5P 691405-48-8P
 691405-50-2P 691405-52-4P 691405-54-6P
 691405-56-8P 691405-58-0P 691405-60-4P
 691405-62-6P 691405-64-8P 691405-66-0P
 691405-68-2P 691405-70-6P 691405-72-8P
 691405-74-0P 691405-76-2P 691405-78-4P
 691405-80-8P 691405-82-0P 691405-84-2P
 691405-86-4P 691405-88-6P 691405-90-0P
 691405-92-2P 691405-94-4P 691405-96-6P
 691405-98-8P 691406-00-5P 691406-02-7P
 691406-04-9P 691406-06-1P 691406-08-3P
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP
 (Preparation)
 (solid-phase combinatorial synthesis of 2,4-diaminopyrimidines via
 Lewis acid-mediated aromatic nucleophilic substitution)

RN 691404-25-8 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-[(2-methoxy-5-methylphenyl)amino]-4-
 [(phenylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691404-24-7
CMF C20 H19 N5 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691404-28-1 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-[[4-(diethylamino)phenyl]amino]-4-[(phenylmethyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691404-27-0
CMF C22 H24 N6



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691404-31-6 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-[(phenylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691404-30-5
 CMF C20 H17 N5 O2



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 691404-34-9 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[(phenylmethyl)amino]-2-[[4-(1-piperidiny)phenyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691404-33-8
 CMF C23 H24 N6



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 691404-36-1 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-[(5-fluoro-2-methylphenyl)amino]-4-
 [(phenylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691404-35-0
 CMF C19 H16 F N5



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 691404-39-4 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-4-
 [(phenylmethyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-38-3
 CMF C24 H20 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-42-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)phenyl]amino]-4-[(phenylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-41-8


CMF C25 H21 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-45-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(4-methyl-2-pyrimidinyl)amino]-4-[(phenylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-44-1

CMF C17 H15 N7




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-48-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-methoxy-5-methylphenyl)amino]-4-
 [[(tetrahydro-2-furanyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA
 INDEX NAME)

CM 1

CRN 691404-47-4


CMF C18 H21 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-51-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[4-(diethylamino)phenyl]amino]-4-
[[tetrahydro-2-furanyl)methyl]amino]-, bis(trifluoroacetate) (9CI) (CA
INDEX NAME)

CM 1

CRN 691404-50-9


CMF C20 H26 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-54-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-
[[tetrahydro-2-furanyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA
INDEX NAME)

CM 1

CRN 691404-53-2


CMF C18 H19 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-57-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[4-(1-piperidiny)phenyl]amino]-4-
[[tetrahydro-2-furanyl)methyl]amino]-, bis(trifluoroacetate) (9CI) (CA
INDEX NAME)

CM 1

CRN 691404-56-5


CMF C21 H26 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-59-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(5-fluoro-2-methylphenyl)amino]-4-
[[tetrahydro-2-furanyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA
INDEX NAME)

CM 1

CRN 691404-58-7


CMF C17 H18 F N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-62-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(5-methyl-2-pyridinyl)amino]-4-[[tetrahydro-2-furanyl]methyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-61-2

CMF C16 H18 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-65-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-4-
[[[tetrahydro-2-furanyl)methyl]amino]-, bis(trifluoroacetate) (9CI) (CA
INDEX NAME)

CM 1

CRN 691404-64-5

CMF C22 H22 N6 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-68-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)phenyl]amino]-4-
[[[tetrahydro-2-furanyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA
INDEX NAME)

CM 1

CRN 691404-67-8


CMF C23 H23 N5 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 691404-71-4 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-[(4-methyl-2-pyrimidinyl)amino]-4-
 [[(tetrahydro-2-furanyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA
 INDEX NAME)

CM 1


CRN 691404-70-3
 CMF C15 H17 N7 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 691404-74-7 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-[(2-methoxy-5-methylphenyl)amino]-4-[[4-
 methylphenyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691404-73-6
 CMF C21 H21 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-77-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[4-(diethylamino)phenyl]amino]-4-[[4-methylphenyl)methyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-76-9


CMF C23 H26 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691404-80-5 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-[[4-methylphenyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX

NAME)

CM 1

CRN 691404-79-2


CMF C21 H19 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-83-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[(4-methylphenyl)methyl]amino]-2-[[4-(1-piperidinyl)phenyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-82-7


CMF C24 H26 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-85-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(5-fluoro-2-methylphenyl)amino]-4-[[(4-methylphenyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-84-9


CMF C20 H18 F N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-87-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[(4-methylphenyl)methyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-86-1

CMF C19 H18 N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-89-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[(4-methylphenyl)methyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-88-3

CMF C25 H22 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-91-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[(4-methylphenyl)methyl]amino]-2-[[3-(phenylmethoxy)phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-90-7


CMF C26 H23 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-93-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[(4-methylphenyl)methyl]amino]-2-[(4-methyl-2-pyrimidinyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-92-9

CMF C18 H17 N7




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-96-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-methoxy-5-methylphenyl)amino]-4-[[3-(1-methylethoxy)propyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-95-2


CMF C19 H25 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-99-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[4-(diethylamino)phenyl]amino]-4-[[3-(1-methylethoxy)propyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-98-5


CMF C21 H30 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-02-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-[[3-(1-methylethoxy)propyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-01-3


CMF C19 H23 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-04-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[3-(1-methylethoxy)propyl]amino]-2-[[4-(1-piperidiny]phenyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-03-5


CMF C22 H30 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-06-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(5-fluoro-2-methylphenyl)amino]-4-[[3-(1-methylethoxy)propyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-05-7


CMF C18 H22 F N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-08-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[3-(1-methylethoxy)propyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-07-9

CMF C17 H22 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-10-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[3-(1-methylethoxy)propyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-09-1

CMF C23 H26 N6 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-12-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[3-(1-methylethoxy)propyl]amino]-2-[[3-(phenylmethoxy)phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-11-5


CMF C24 H27 N5 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 691405-14-8 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[[3-(1-methylethoxy)propyl]amino]-2-[(4-methyl-2-pyrimidinyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691405-13-7
 CMF C16 H21 N7 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 691405-16-0 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[(2-methoxy-5-methylphenyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691405-15-9
 CMF C21 H19 Cl2 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-18-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[[4-(diethylamino)phenyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-17-1


CMF C23 H24 Cl2 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691405-20-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-, mono(trifluoroacetate) (9CI) (CA

INDEX NAME)

CM 1

CRN 691405-19-3


CMF C21 H17 Cl2 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-22-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-[(2,4-dichlorophenyl)ethyl]amino]-2-[[4-(1-piperidinyl)phenyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-21-7


CMF C24 H24 Cl2 N6



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 691405-24-0 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[(5-fluoro-2-methylphenyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691405-23-9
 CMF C20 H16 Cl2 F N5



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 691405-26-2 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-25-1
 CMF C19 H16 Cl2 N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-28-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-27-3

CMF C25 H20 Cl2 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-30-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[[3-(phenylmethoxy)phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-29-5


CMF C26 H21 Cl2 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-32-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[(4-methyl-2-pyrimidinyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-31-9

CMF C18 H15 Cl2 N7




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-34-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[(2-methoxy-5-methylphenyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-33-1


CMF C23 H25 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-37-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[4-(diethylamino)phenyl]amino]-4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-36-4


CMF C25 H30 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-39-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-38-6


CMF C23 H23 N5 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-41-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[[4-(1-piperidinyl)phenyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-40-0


CMF C26 H30 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-43-3 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[(5-fluoro-2-methylphenyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-42-2


CMF C22 H22 F N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-45-5 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-44-4

CMF C21 H22 N6 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-48-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-47-7

CMF C27 H26 N6 O3




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-50-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[[3-(phenylmethoxy)phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-49-9


CMF C28 H27 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-52-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[(4-methyl-2-pyrimidinyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-51-3

CMF C20 H21 N7 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-54-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2-methoxy-5-methylphenyl)amino]-4-[[2-methoxyphenyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-53-5


CMF C21 H21 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-56-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[4-(diethylamino)phenyl]amino]-4-[[2-methoxyphenyl)methyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-55-7


CMF C23 H26 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-58-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-[[2-methoxyphenyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-57-9


CMF C21 H19 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-60-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[(2-methoxyphenyl)methyl]amino]-2-[[4-(1-piperidinyl)phenyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-59-1


CMF C24 H26 N6 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 691405-62-6 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-[(5-fluoro-2-methylphenyl)amino]-4-[[2-methoxyphenyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691405-61-5
 CMF C20 H18 F N5 O



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 691405-64-8 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[[2-methoxyphenyl)methyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-63-7
 CMF C19 H18 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-66-0 CAPLUS

CA 5-Pyrimidinecarbonitrile, 4-[[2-methoxyphenyl)methyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-65-9

CMF C25 H22 N6 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 691405-68-2 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[[(2-methoxyphenyl)methyl]amino]-2-[[3-(phenylmethoxy)phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1.

CRN 691405-67-1
 CMF C26 H23 N5 O2



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 691405-70-6 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-[[(2-methoxyphenyl)methyl]amino]-2-[[4-methyl-2-pyrimidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-69-3
 CMF C18 H17 N7 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-72-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[4-(4-fluorophenyl)methyl]amino]-2-[(2-methoxy-5-methylphenyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-71-7


CMF C20 H18 F N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-74-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[4-(diethylamino)phenyl]amino]-4-[[4-(fluorophenyl)methyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-73-9


CMF C22 H23 F N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-76-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-[[4-(fluorophenyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-75-1


CMF C20 H16 F N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-78-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[4-(4-fluorophenyl)methyl]amino]-2-[[4-(1-piperidiny]phenyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-77-3


CMF C23 H23 F N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-80-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(5-fluoro-2-methylphenyl)amino]-4-[[4-(4-fluorophenyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691405-79-5
CMF C19 H15 F2 N5



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691405-82-0 CAPLUS
CM 5-Pyrimidinecarbonitrile, 4-[[[(4-fluorophenyl)methyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691405-81-9
CMF C18 H15 F N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691405-84-2 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[(4-fluorophenyl)methyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691405-83-1
CMF C24 H19 F N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691405-86-4 CAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[[(4-fluorophenyl)methyl]amino]-2-[[3-(phenylmethoxy)phenyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691405-85-3
CMF C25 H20 F N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-88-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[(4-fluorophenyl)methyl]amino]-2-[(4-methyl-2-pyrimidinyl)amino]]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-87-5


CMF C17 H14 F N7



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691405-90-0 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-[(2-methoxy-5-methylphenyl)amino]-4-(propylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691405-89-7
CMF C16 H19 N5 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 691405-92-2 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-[[4-(diethylamino)phenyl]amino]-4-(propylamino)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691405-91-1
CMF C18 H24 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-94-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-(propylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-93-3


CMF C16 H17 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-96-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[4-(1-piperidinyl)phenyl]amino]-4-(propylamino)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-95-5


CMF C19 H24 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-98-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(5-fluoro-2-methylphenyl)amino]-4-(propylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-97-7


CMF C15 H16 F N5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691406-00-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(5-methyl-2-pyridinyl)amino]-4-(propylamino)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-99-9

CMF C14 H16 N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691406-02-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-4-(propylamino)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691406-01-6

CMF C20 H20 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691406-04-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)phenyl]amino]-4-(propylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691406-03-8


CMF C21 H21 N5 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691406-06-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(4-methyl-2-pyrimidinyl)amino]-4-(propylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691406-05-0

CMF C13 H15 N7




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691406-08-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(5-methyl-2-pyridinyl)amino]-4-
[(phenylmethyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691406-07-2

CMF C18 H16 N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:142963 CAPLUS

DN 140:199334

TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases

IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Clough, Jeffrey; Keim, Holger; Sylvain, Catherine; Li, Hui; Bhamidipati, Somasekhar

PA Rigel Pharmaceuticals, USA

SO PCT Int. Appl., 811 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014382	A1	20040219	WO 2003-US24087	20030729
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2492325	AA	20040219	CA 2003-2492325	20030729
	AU 2003265336	A1	20040225	AU 2003-265336	20030729
	EP 1534286	A1	20050601	EP 2003-784871	20030729
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013059	A	20050705	BR 2003-13059	20030729
	CN 1678321	A	20051005	CN 2003-821120	20030729
	JP 2006514989	T2	20060518	JP 2005-506142	20030729
	US 2005038243	A1	20050217	US 2004-858343	20040601
	US 7060827	B2	20060613		
	US 2005209230	A1	20050922	US 2004-911684	20040803
	SE 2005000203	A	20050329	SE 2005-203	20050127
	NO 2005001069	A	20050228	NO 2005-1069	20050228
	US 2006025410	A1	20060202	US 2005-149105	20050608
	US 2006035916	A1	20060216	US 2005-148746	20050608
	US 2006058292	A1	20060316	US 2005-149418	20050608
	US 2006135543	A1	20060622	US 2005-299207	20051208
PRAI	US 2002-399673P	P	20020729		
	US 2003-443949P	P	20030131		
	US 2003-452339P	P	20030306		
	US 2003-631029	A	20030729		
	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-434277P	P	20021217		
	US 2003-355543	A1	20030131		
	WO 2003-US24087	W	20030729		
	US 2004-858343	A3	20040601		

OS MARPAT 140:199334

AB The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compds., as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Title compds. I [wherein L1 and L2 = independently a bond or a

linker; R2 = (un)substituted alkyl, (hetero)cycloalkyl, or (hetero)aryl; R4 = H or R2; R5 = R6 or (un)substituted alkyl, alkenyl, or alkynyl; R6 = independently H, an electroneg. group, protected alc. or thiol, haloalkyl(oxy), halo, CN, NC, OCN, SCN, NO, NO2, N3, or (un)substituted amino, sulfamoyl(oxy), acyl, carboxy, carbamoyl, (hetero)aryl(alkyl), etc.; with provisos and exclusions; and salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with 4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC50 values of 4.5 μ M and 4.4 μ M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. Specific examples of autoimmune diseases that can be treated or prevented with I and their pharmaceutical compns. include rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis (no data).



IT 575477-28-0P 575477-66-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases).



RN 575477-28-0 CAPLUS

CN Benzoic acid, [[[5-cyano-2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 575477-66-6 CAPLUS

CN Benzoic acid, [[[5-cyano-2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:610204 CAPLUS

DN 139:164801

TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor
modulators for treatment of allergic diseases, inflammatory conditions,
and tissue destruction

IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Molineaux, Susan;
Holland, Sacha J.; Clough, Jeffrey; Keim, Holger; Bhamidipati, Somasekhar;
Sylvain, Catherine; Li, Weigun; Rossi, Alexander B.

PA Rigel Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 648 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063794	A2	20030807	WO 2003-US3022	20030131
	WO 2003063794	A3	20031204		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2474277	AA	20030807	CA 2003-2474277	20030131
	US 2004029902	A1	20040212	US 2003-355543	20030131
	EP 1471915	A2	20041103	EP 2003-707654	20030131
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005516046	T2	20050602	JP 2003-563490	20030131
	CN 1625400	A	20050608	CN 2003-803180	20030131
	BR 2003007355	A	20060411	BR 2003-7355	20030131
	US 2005038243	A1	20050217	US 2004-858343	20040601
	US 7060827	B2	20060613		
	US 2005209230	A1	20050922	US 2004-911684	20040803
	NO 2004003632	A	20041026	NO 2004-3632	20040831
	US 2006025410	A1	20060202	US 2005-149105	20050608
	US 2006035916	A1	20060216	US 2005-148746	20050608
	US 2006058292	A1	20060316	US 2005-149418	20050608
	US 2006135543	A1	20060622	US 2005-299207	20051208
PRAI	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-399673P	P	20020729		
	US 2002-434277P	P	20021217		
	US 2003-355543	A1	20030131		
	WO 2003-US3022	W	20030131		
	US 2004-858343	A3	20040601		

OS MARPAT 139:164801

AB Title compds. I [wherein L1 and L2 = independently a bond or a linker; R2 = (un)substituted alkyl, (hetero)cycloalkyl, or (hetero)aryl; R4 = H or R2; R5 = R6 or (un)substituted alkyl, alkenyl, or alkynyl; R6 = independently H, an electroneg. group, protected alc. or thiol, haloalkyl(oxy), halo, CN, NC, OCN, SCN, NO, NO2, N3, or (un)substituted

amino, sulfamoyl(oxy), acyl, carboxy, carbamoyl, (hetero)aryl(alkyl), etc.; with provisos and exclusions; and salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with 4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC50 values of 4.5 μ M and 4.4 μ M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. The treatment and prevention of allergic diseases, low grade scarring, diseases associated with tissue destruction, diseases associated with tissue inflammation, inflammation, and scarring are targeted uses (no data).



IT 575477-28-0P 575477-66-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction)



RN 575477-28-0 CAPLUS

CN Benzoic acid, [[[5-cyano-2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 575477-66-6 CAPLUS


CN Benzoic acid, [[[5-cyano-2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:319721 CAPLUS
 DN 138:321292
 TI Preparation of 2,4,5-trisubstituted pyrimidines as cyclin dependent kinase inhibitors
 IN Dahmann, Georg; Himmelsbach, Frank; Wittneben, Helmut; Pautsch, Alexander; Prokopowicz, Anthony S.; Krist, Bernd; Schnapp, Gisela; Steegmaier, Martin; Lenter, Martin; Schoop, Andreas; Steurer, Steffen; Spevak, Walter
 PA Boehringer Ingelheim Pharma K.-G., Germany; Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International G.m.b.H.
 SO PCT Int. Appl., 278 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032997	A1	20030424	WO 2002-EP11453	20021014
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2463989	AA	20030424	CA 2002-2463989	20021014
	EP 1438053	A1	20040721	EP 2002-774710	20021014
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005509624	T2	20050414	JP 2003-535800	20021014
	US 2003171359	A1	20030911	US 2002-271763	20021016
	US 2006100211	A1	20060511	US 2005-313380	20051221
PRAI	US 2001-330145P	P	20011017		
	WO 2002-EP11453	W	20021014		
	US 2002-271763	A3	20021016		

OS MARPAT 138:321292
 AB Title compds. I [R1 = H, alkyl; R2 = (un)substituted alkyl; R3 = H, alkyl; R4 = (un)substituted alkyl; R5 = halo] and their pharmaceutically acceptable salts were prepared. For example, condensation of thiocyanatopyrimide II, e.g., prepared from 3,4-dichloroaniline and 2-chloro-4-thiocyanato-5-nitropyrimidine in one step, and acetylaminoethylamine provided trisubstituted pyrimidine III in 88% yield. In CDK1/CyclinB1 kinase inhibition studies, 88-examples of compds. I exhibited IC50 values more than 100 nM. Compds. I are claimed useful for the treatment of diseases characterized by abnormal cell proliferation.
 IT 514830-61-6P, 2-(3,4-Dichlorophenylamino)-4-(2-acetylaminoethylamino)-5-cyanopyrimidine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of trisubstituted pyrimidines as cyclin dependent kinase inhibitors)
 RN 514830-61-6 CAPLUS
 CN Acetamide, N-[2-[[5-cyano-2-[(3,4-dichlorophenyl)amino]-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:22859 CAPLUS

DN 138:89818

TI Preparation of pyridine and pyrimidine N-heterocyclic p38 kinase inhibitors for treating TNF- α mediated disorders

IN Ahmed, Gulzar; Metzger, Axel; Wroblewski, Stephen T.; Henderson, Ian; Wen, James; Diller, David J.; Leftheris, Katerina

PA Bristol-Myers Squibb Company, USA; Pharmacoepia, Inc.

SO PCT Int. Appl., 134 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002544	A1	20030109	WO 2002-US20341	20020626
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, LS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2451128	AA	20030109	CA 2002-2451128	20020626
US 2003139435	A1	20030724	US 2002-183179	20020626
EP 1406875	A1	20040414	EP 2002-746724	20020626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004535447	T2	20041125	JP 2003-508925	20020626
PRAI US 2001-301020P	P	20010626		
WO 2002-US20341	W	20020626		

OS MARPAT 138:89818

AB N-heterocyclic compds. (shown as I; variables defined below; e.g. 3-[3-cyano-6-[(2,2-dimethylpropyl)methylamino]-5-fluoropyridin-2-ylamino]-N-methoxy-4-methylbenzamide and 3-[5-cyano-6-[(2,2-dimethylpropyl)methylamino]-2-methylsulfanylpurimidin-4-ylamino]-4,N-dimethylbenzamide) that block cytokine production via inhibition of p38 kinase (no data) are disclosed. In one embodiment, compds. of the present invention are represented by Formula (I). Methods of production, pharmaceutical compns. and methods of treating conditions associated with inappropriate p38 kinase activity or TNF- α expression using compds. of the present invention are also disclosed. For I: 1 or 2 of W, Y and X are :N-; 1 of W, Y and X = :C-CN, :C-F, :C-NO₂, :C-Br, :C-NH₂, :C-NHC(O)CH₃ and :C-Cl; the remaining W, Y or X is :CH-; V is -NR₅-; Z is halogen or -N(R₁)(R₂); R₁ and R₂ = H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl or substituted heterocyclyl; R₅ is H or alkyl; R₆ = (un)substituted aryl; R₁₁ is H, halogen, O-R₃₅ or -N(R₁₂)(R₁₃); R₁₂ is H, alkyl, or substituted alkyl; R₁₃ is -(CH₂)_mR₁₄; -N(R₁₂)(R₁₃) taken together may form a heterocyclyl or substituted heterocyclyl; m = 0-3; other variables are defined in the claims. Although the methods of preparation are not claimed, .apprx.30 example prepns. are included.

IT 482344-85-4P, 3-[[5-Cyano-4-[(2,2-dimethylpropyl)methylamino]pyrimidin-2-yl]amino]-4,N-dimethylbenzamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyridine and pyrimidine N-heterocyclic p38 kinase inhibitors for treating TNF- α mediated disorders)


RN 482344-85-4 CAPLUS

CN Benzamide, 3-[[5-cyano-4-[(2,2-dimethylpropyl)methylamino]-2-pyrimidinyl]amino]-N,4-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:641097 CAPLUS
 DN 138:122613
 TI Structure-Activity Relationship Studies of Ethyl 2-[(3-Methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: An Inhibitor of AP-1 and NF- κ B Mediated Gene Expression
 AU Palanki, Moorthy S. S.; Gayo-Fung, Leah M.; Shevlin, Graziella I.; Erdman, Paul; Sato, Mark; Goldman, Mark; Ransone, Lynn J.; Spooner, Cheryl
 CS Celgene Signal Research Division, San Diego, CA, 92121, USA
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(18), 2573-2577
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 138:122613
 AB Several analogs of Et 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate (I) were synthesized and tested as inhibitors of AP-1 and NF- κ B mediated transcriptional activation in Jurkat T cells. From our SAR work, Et 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))-N-methylamino]-4-(trifluoromethyl)-pyrimidine-5-carboxylate was identified as a novel and potent inhibitor.
 IT 488800-17-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn of pyrrolinylaminopyrimidine analogs from β -keto esters and their activity as inhibitors of AP-1 and NF- κ B mediated gene expression)
 RN 488800-17-5 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 2-[(2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-1-yl)amino]-4-ethyl- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:51442 CAPLUS
 DN 136:102398
 TI Preparation of 4-amino-2-anilino-5-cyanopyrimidines as antitumor agents
 IN Thomas, Andrew Peter; Newcombe, Nicholas John; Heaton, David William
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SO PCT Int. Appl., 88 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004429	A1	20020117	WO 2001-GB3084	20010706
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2415486	AA	20020117	CA 2001-2415486	20010706
	EP 1303496	A1	20030423	EP 2001-947671	20010706
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001012420	A	20030624	BR 2001-12420	20010706
	JP 2004502763	T2	20040129	JP 2002-509296	20010706
	NZ 523357	A	20040730	NZ 2001-523357	20010706
	EE 200300020	A	20041015	EE 2003-20	20010706
	TW 221470	B1	20041001	TW 2001-90116869	20010710
	ZA 2003000079	A	20040505	ZA 2003-79	20030103
	US 2003216406	A1	20031120	US 2003-332275	20030107
	US 6908920	B2	20050621		
	BG 107451	A	20030930	BG 2003-107451	20030108
	NO 2003000146	A	20030110	NO 2003-146	20030110
PRAI	GB 2000-16877	A	20000711		
	WO 2001-GB3084	W	20010706		

OS MARPAT 136:102398

AB The title compds. [I; R1 = halo, NO2, CN, etc.; p = 0-4; R2 = sulfamoyl, EB; q = 0-2; p + q = 1-5; R3 = H, alkyl, alkenyl, etc.; R4 = alkyl, alkenyl, alkynyl, etc.; or NR3R4 = (un)substituted heterocyclyl such morpholino; B = alkyl, alkenyl, Ph, etc.; E = CO, NHCO, CONH, etc.], useful as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, were prepared Thus, reacting 2-chloro-5-cyano-4-morpholinopyrimidine with 4-[N-(3-isopropylaminopropyl)sulfamoyl]aniline in the presence of 1N HCl in 2-butanol afforded 19% I [R2 = 4-[N-(3-isopropylaminopropyl)sulfamoyl]; R1 = H; NR3R4 = morpholino] which showed IC50 of 0.148 μ M against CDK2. The title compds. I showed IC50's in the range 1 μ M to 1 nM when tested in assay measuring inhibition of cell growth.

IT 389604-30-2P 389604-31-3P 389604-32-4P
 389604-33-5P 389604-34-6P 389604-35-7P
 389604-36-8P 389604-37-9P 389604-38-0P
 389604-39-1P 389604-40-4P 389604-41-5P
 389604-42-6P 389604-43-7P 389604-44-8P


389604-45-9P 389604-46-0P 389604-47-1P
 389604-49-3P 389604-57-3P 389604-64-2P
 389604-65-3P 389604-66-4P 389604-67-5P
 389604-68-6P 389604-69-7P 389604-70-0P
 389604-71-1P 389604-72-2P 389604-73-3P
 389604-74-4P 389604-75-5P 389604-76-6P
 389604-77-7P 389604-78-8P 389604-79-9P
 389604-81-3P 389604-83-5P 389604-84-6P
 389604-86-8P 389604-87-9P 389604-88-0P
 389605-07-6P 389605-08-7P 389605-09-8P
 389605-10-1P 389605-11-2P 389605-12-3P
 389605-13-4P 389605-14-5P 389605-15-6P
 389605-16-7P 389605-17-8P 389605-18-9P
 389605-19-0P 389605-20-3P 389605-21-4P
 389605-22-5P 389605-23-6P 389605-24-7P
 389605-25-8P 389605-26-9P 389605-27-0P
 389605-28-1P 389605-29-2P 389605-30-5P
 389605-31-6P 389605-32-7P 389605-33-8P
 389605-34-9P 389605-35-0P 389605-36-1P
 389605-37-2P 389605-38-3P 389605-39-4P
 389605-40-7P 389605-41-8P 389605-42-9P
 389605-43-0P 389605-44-1P 389605-45-2P
 389605-46-3P 389605-47-4P 389605-48-5P
 389605-49-6P 389605-51-0P 389605-52-1P
 389605-53-2P 389605-54-3P 389605-55-4P
 389605-56-5P 389605-57-6P 389605-58-7P
 389605-60-1P 389605-61-2P 389605-62-3P
 389605-63-4P 389605-64-5P 389605-67-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 4-amino-2-anilino-5-cyanopyrimidines as antitumor agents)


RN 389604-30-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2-methylpropyl)amino]-2-
 pyrimidinyl]amino]-N-[3-[(1-methylethyl)amino]propyl]- (9CI) (CA INDEX
 NAME)




RN 389604-31-3 CAPLUS


CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[3-
 [(1-methylethyl)amino]propyl]- (9CI) (CA INDEX NAME)




RN 389604-32-4 CAPLUS
 CN Benzenesulfonamide, 4-[[5-cyano-4-[(2-fluoroethyl)amino]-2-pyrimidinyl]amino]-N-[3-[(1-methylethyl)amino]propyl]- (9CI) (CA INDEX NAME)




RN 389604-33-5 CAPLUS
 CN Benzenesulfonamide, 4-[[5-cyano-4-[(3-ethoxypropyl)amino]-2-pyrimidinyl]amino]-N-[3-[(1-methylethyl)amino]propyl]- (9CI) (CA INDEX NAME)



RN 389604-34-6 CAPLUS
 CN Benzenesulfonamide, 4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]-N-[3-[(1-methylethyl)amino]propyl]- (9CI) (CA INDEX NAME)




RN 389604-35-7 CAPLUS
 CN Benzenesulfonamide, 4-[[5-cyano-4-(methyl-2-propenylamino)-2-pyrimidinyl]amino]-N-[3-[(1-methylethyl)amino]propyl]- (9CI) (CA INDEX NAME)




RN 389604-36-8 CAPLUS

CN Glycine, N-[5-cyano-2-[[4-[[[3-[(1-methylethyl)amino]propyl]amino]sulfonyl]phenyl]amino]-4-pyrimidinyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 389604-37-9 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2-cyanoethyl)methylamino]-2-pyrimidinyl]amino]-N-[3-[(1-methylethyl)amino]propyl]- (9CI) (CA INDEX NAME)



RN 389604-38-0 CAPLUS


CN Benzenesulfonamide, 4-[[5-cyano-4-(diethylamino)-2-pyrimidinyl]amino]-N-[3-[(1-methylethyl)amino]propyl]- (9CI) (CA INDEX NAME)



RN 389604-39-1 CAPLUS


CN Benzenesulfonamide, 4-[[5-cyano-4-[(2-methoxyethyl)methylamino]-2-

pyrimidinyl]amino]-N-[3-[(1-methylethyl)amino]propyl]- (9CI) (CA INDEX NAME)




RN 389604-40-4 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[[3-(4-morpholinyl)propyl]amino]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389604-41-5 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(diethylamino)-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 389604-42-6 CAPLUS


CN Benzenesulfonamide, 4-[[5-cyano-4-[(2-methylpropyl)amino]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 389604-43-7 CAPLUS


CN Benzenesulfonamide, 4-[[5-cyano-4-(methyl-2-propenylamino)-2-

pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389604-44-8 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2-fluoroethyl)amino]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389604-45-9 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2-cyanoethyl)methylamino]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389604-46-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2-(dimethylamino)ethyl)amino]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389604-47-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(cyanomethyl)amino]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389604-49-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2-methoxyethyl)methylamino]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 389604-57-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 389604-64-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(methylamino)-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 389604-65-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(2-propynylamino)-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 389604-66-4 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(cyanomethyl)amino]-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 389604-67-5 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[methyl(2,2,2-trifluoroethyl)amino]-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 389604-68-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2-methoxyethyl)amino]-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 389604-69-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 389604-70-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]-N-pentyl- (9CI) (CA INDEX NAME)




RN 389604-71-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 389604-72-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(butylamino)-2-[[4-(methylsulfonyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 389604-73-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2,2,2-trifluoroethyl)amino]-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 389604-74-4 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2,2,2-trifluoroethyl)amino]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 389604-75-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(ethylamino)-2-[[4-(methylsulfonyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 389604-76-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 389604-77-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389604-78-8 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2,2,2-trifluoroethyl)amino]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389604-79-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-[bis(2-cyanoethyl)amino]-5-cyano-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389604-81-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(cyclopropylmethyl)amino]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389604-83-5 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[[[(tetrahydro-2-furanyl)methyl]amino]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389604-84-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(3-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389604-86-8 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(cyclohexylethylamino)-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389604-87-9 CAPLUS

CN Glycine, N-[5-cyano-2-[[4-[[[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]phenyl]amino]-4-pyrimidinyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 389604-88-0 CAPLUS

CN β -Alanine, N-[5-cyano-2-[[4-[[[(tetrahydro-2-furanyl)methyl]amino]sulfonyl]phenyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 389605-07-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)



RN 389605-08-7 CAPLUS


CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-(3-ethoxypropyl)- (9CI) (CA INDEX NAME)



RN 389605-09-8 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 389605-10-1 CAPLUS


CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[3-[2-(dimethylamino)ethoxy]propyl]- (9CI) (CA INDEX NAME)



RN 389605-11-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)


10/812,293




RN 389605-12-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 389605-13-4 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[2-(1-ethyl-2-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 389605-14-5 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 389605-15-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 389605-16-7 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 389605-17-8 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 389605-18-9 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 389605-19-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 389605-20-3 CAPLUS

CN Acetamide, N-[2-[[[4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]phenyl]sulfonyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 389605-21-4 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 389605-22-5 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 389605-23-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 389605-24-7 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-(1,4-dioxan-2-ylmethyl)- (9CI) (CA INDEX NAME)




RN 389605-25-8 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 389605-26-9 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-(2-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 389605-27-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-2-propynyl- (9CI) (CA INDEX NAME)




RN 389605-28-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-(3-hydroxy-2,2-dimethylpropyl)- (9CI) (CA INDEX NAME)




RN 389605-29-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 389605-30-5 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-(2-(2-hydroxyethoxy)ethyl)- (9CI) (CA INDEX NAME)




RN 389605-31-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 389605-32-7 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-(5-hydroxypentyl)- (9CI) (CA INDEX NAME)




RN 389605-33-8 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-(2-hydroxybutyl)- (9CI) (CA INDEX NAME)




RN 389605-34-9 CAPLUS

CN Benzenesulfonamide, N-(2-cyanoethyl)-4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 389605-35-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]-N-[2-(ethylthio)ethyl]- (9CI) (CA INDEX NAME)



RN 389605-36-1 CAPLUS


CN Benzenesulfonamide, 4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 389605-37-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 389605-38-3 CAPLUS
 CN Benzenesulfonamide, 4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 389605-39-4 CAPLUS
 CN Benzenesulfonamide, 4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 389605-40-7 CAPLUS

CN Benzenesulfonamide, 4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]-N-(2-cyclopentylethyl)- (9CI) (CA INDEX NAME)




RN 389605-41-8 CAPLUS

CN Benzenesulfonamide, N-(3-amino-2-hydroxypropyl)-4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 389605-42-9 CAPLUS

CN Benzenesulfonamide, 4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]-N-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 389605-43-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2,2,2-trifluoroethyl)amino]-2-pyrimidinyl]amino]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 389605-44-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2,2,2-trifluoroethyl)amino]-2-pyrimidinyl]amino]-N-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)




RN 389605-45-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2,2,2-trifluoroethyl)amino]-2-pyrimidinyl]amino]-N-[2-(2-hydroxyethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 389605-46-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2,2,2-trifluoroethyl)amino]-2-pyrimidinyl]amino]-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 389605-47-4 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2,2,2-trifluoroethyl)amino]-2-pyrimidinyl]amino]-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)




RN 389605-48-5 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2,2,2-trifluoroethyl)amino]-2-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 389605-49-6 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2,3-dihydroxypropyl)amino]-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 389605-51-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(methyl-2-propynylamino)-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 389605-52-1 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[[[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amino]-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 389605-53-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 389605-54-3 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[[2-(2-hydroxyethoxy)ethyl]amino]-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 389605-55-4 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2-hydroxyethyl)amino]-2-pyrimidinyl]amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 389605-56-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(2-hydroxyethyl)amino]-2-[[4-(methylsulfonyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 389605-57-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(2-methylpropyl)amino]-2-[[4-(methylsulfonyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 389605-58-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(cyclopropylmethyl)amino]-2-[[4-(methylsulfonyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 389605-60-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(ethylamino)-2-[[4-(ethylsulfonyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 389605-61-2 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 389605-62-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(methylamino)-2-[[4-(methanesulfonyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 389605-63-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[4-(methanesulfonyl)phenyl]amino]-4-(propylamino)- (9CI) (CA INDEX NAME)




RN 389605-64-5 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-N-[2-hydroxy-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 389605-67-8 CAPLUS

CN Benzenesulfonamide, 4-[[5-cyano-4-[(2,2,2-trifluoroethyl)amino]-2-pyrimidinyl]amino]-N-[2-hydroxy-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




IT 389606-53-5P 389606-54-6P 389606-55-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-amino-2-anilino-5-cyanopyrimidines as antitumor agents)


RN 389606-53-5 CAPLUS

CN Benzenesulfonyl fluoride, 4-[[5-cyano-4-(ethylamino)-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)




RN 389606-54-6 CAPLUS

CN Benzenesulfonyl fluoride, 4-[[4-(butylamino)-5-cyano-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)



RN 389606-55-7 CAPLUS

CN Benzenesulfonyl fluoride, 4-[[5-cyano-4-[(2,2,2-trifluoroethyl)amino]-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:600713 CAPLUS

DN 129:316187

TI Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8H-pyrido[2,3-d]pyrimidines: Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors

AU Boschelli, Diane H.; Wu, Zhipei; Klutchko, Sylvester R.; Showalter, H. D. Hollis; Hamby, James M.; Lu, Gina H.; Major, Terry C.; Dahring, Tawny K.; Batley, Brian; Panek, Robert L.; Keiser, Joan; Hartl, Brian G.; Kraker, Alan J.; Klohs, Wayne D.; Roberts, Bill J.; Patmore, Sandra; Elliott, William L.; Steinkampf, Randy; Bradford, Laura A.; Hallak, Hussein; Doherty, Annette M.

CS Department of Medicinal Chemistry, Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Ann Arbor, MI, 48105, USA

SO Journal of Medicinal Chemistry (1998), 41(22), 4365-4377

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB Screening of a compound library led to the identification of 2-amino-6-(2,6-dichlorophenyl)-8-methylpyrido[2,3-d]pyrimidine (I) as a inhibitor of the platelet-derived growth factor receptor (PDGFr), fibroblast growth factor receptor (FGFr), and c-src tyrosine kinases (TKs). Replacement of the primary amino group at C-2 of I with a 4-(N,N-diethylaminoethoxy)phenylamino group gave a compound, which had greatly increased activity against all three TKs. In the present work, variation of the aromatic group at C-6 and of the alkyl group at N-8 of the pyrido[2,3-d]pyrimidine core provided several analogs that retained potency, including derivs. that were biased toward inhibition of the TK activity of PDGFr. Analogs of the 4-[(N,N-diethylaminoethoxy)phenylamino]-substituted derivative with a 3-thiophene or an unsubstituted Ph group at C-6 were the most potent inhibitors. One compound, 2-[4-[2-(diethylamino)ethoxy]phenylamino]-8-ethyl-6-phenyl-8H-pyrido[2,3-d]pyrimidin-7-one had IC50 values of 31, 88, and 31 nM against PDGFr, FGFr, and c-src TK activity, resp.,. It was active in a variety of PDGF-dependent cellular assay and blocked the in vivo growth of three PDGF-dependent tumor lines.


IT 214983-14-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and tyrosine kinase inhibitory activity of aminopyrido[2,3-d]pyrimidines)

RN 214983-14-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(methylamino)-2-(phenylamino)- (9CI) (CA INDEX NAME)



Intermediate

RE.CNT 56

THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d his

(FILE 'HOME' ENTERED AT 17:26:14 ON 20 SEP 2006)

FILE 'REGISTRY' ENTERED AT 17:26:26 ON 20 SEP 2006

L1 STRUCTURE UPLOADED
 L2 23 S L1 SSS SAM
 L3 STRUCTURE UPLOADED
 L4 STRUCTURE UPLOADED
 L5 STRUCTURE UPLOADED
 L6 15 S L5 SSS SAM
 L7 STRUCTURE UPLOADED
 L8 13 S L7 SSS SAM
 L9 274 S L7 SSS FUL

FILE 'CAPLUS' ENTERED AT 17:46:46 ON 20 SEP 2006
 L10 10 S L9

FILE 'CAOLD' ENTERED AT 17:47:27 ON 20 SEP 2006

=> s 19

L11 0 L9

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.44

233.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-7.50

STN INTERNATIONAL LOGOFF AT 17:47:39 ON 20 SEP 2006